Cost-Effectiveness Analysis of Using Everolimus or Axitinib in Patients with Metastatic Renal Cell Carcinoma WHO Have Failed to Use of Pazopanib or Sunitinib in First-Line Treatment
Abstract
Authors
ME Romero Prada LM Huerfano NC Roa Cardenas